Real‐world comparative effectiveness, safety, and health care costs of oral anticoagulants in non‐valvular atrial fibrillation patients in the United States Department of Defense population

by | May 8, 2019 | Cardiovascular, Publication

Abstract Authors: Gupta K, Trocio J, Keshishian A, Zhang Q, Dina O, Mardekian J, Rosenblatt L, Liu X, HedeS, Nadkarni A, Shank T. Background: The ARISTOTLE trial demonstrated that apixaban had significantly lower rates of stroke/systemic embolism (SE) and major...

A real‐world observational study of hospitalization and health care costs among non‐valvular atrial fibrillation patients prescribed oral anticoagulants in the US Medicare population

by | May 6, 2019 | Cardiovascular, Publication

Abstract Authors: Amin A, Keshishian A, Trocio J, Dina O, Le H, Rosenblatt L, Liu X, Mardekian J, Zhang Q,Baser O, Nadkarni A, Vo L. Background: Clinical trials have shown that direct oral anticoagulants (DOACs)-including dabigatran, rivaroxaban, apixaban, and...

Apixaban 5 and 2.5 mg twice‐daily versus warfarin for stroke prevention in nonvalvular atrial fibrillation patients: comparative effectiveness and safety evaluated using a propensity‐score‐matched approach

by | May 4, 2019 | Cardiovascular, Publication

Abstract Authors: Li X, Keshishian A, Hamilton M, Horblyuk R, Gupta K, Luo X, Mardekian J, Friend K,Nadkarni A, Pan X, Lip GYH, Deitelzweig S. Prior real-world studies have shown that apixaban is associated with a reduced risk of stroke/systemic embolism (stroke/SE)...

Real‐world comparison of all‐cause hospitalizations, hospitalizations due to stroke and major bleeding, and costs for NVAF patients prescribed oral anticoagulants in a US health plan

by | May 2, 2019 | Cardiovascular, Publication

Abstract Authors: Amin A, Keshishian A, Vo L, Zhang Q, Dina O, Patel C, Odell K, Trocio J. Aims: To compare the risk of all-cause hospitalization and hospitalizations due to stroke/systemic embolism (SE) and major bleeding, as well as associated healthcare costs...